Intraperitoneal Glucose Transport to Micrometastasis: A Multimodal In Vivo Imaging Investigation in a Mouse Lymphoma Model.
Animals
Disease Models, Animal
Fluorodeoxyglucose F18
/ metabolism
Glucose
/ metabolism
Injections, Intraperitoneal
Lymphatic Metastasis
Lymphoma
/ diagnostic imaging
Mice
Mice, Inbred BALB C
Multimodal Imaging
/ methods
Neoplasm Micrometastasis
Positron-Emission Tomography
/ methods
Radiopharmaceuticals
/ metabolism
Tomography, X-Ray Computed
/ methods
Cerenkov light imaging
FDG
PET/MRI
fiberoptic microscopy
image-guided surgery
lymphoma
micrometastasis
molecular imaging
peritoneal metastasis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 Apr 2021
23 Apr 2021
Historique:
received:
01
03
2021
revised:
16
04
2021
accepted:
19
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
29
5
2021
Statut:
epublish
Résumé
Bc-DLFL.1 is a novel spontaneous, high-grade transplantable mouse B-cell lymphoma model for selective serosal propagation. These cells attach to the omentum and mesentery and show dissemination in mesenteric lymph nodes. We aimed to investigate its early stage spread at one day post-intraperitoneal inoculation of lymphoma cells (n = 18 mice), and its advanced stage at seven days post-inoculation with in vivo [18F]FDG-PET and [18F]PET/MRI, and ex vivo by autoradiography and Cherenkov luminescence imaging (CLI). Of the early stage group, nine animals received intraperitoneal injections, and nine received intravenous [18F]FDG injections. The advanced stage group (n = 3) received intravenous FDG injections. In the early stage, using autoradiography we observed a marked accumulation in the mesentery after intraperitoneal FDG injection. Using other imaging methods and autoradiography, following the intravenous injection of FDG no accumulations were detected. At the advanced stage, tracer accumulation was clearly detected in mesenteric lymph nodes and in the peritoneum after intravenous administration using PET. We confirmed the results with immunohistochemistry. Our results in this model highlight the importance of local FDG administration during diagnostic imaging to precisely assess early peritoneal manifestations of other malignancies (colon, stomach, ovary). These findings also support the importance of applying topical therapies, in addition to systemic treatments in peritoneal cancer spread.
Identifiants
pubmed: 33922728
pii: ijms22094431
doi: 10.3390/ijms22094431
pmc: PMC8123046
pii:
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Seventh Framework Programme
ID : 606614
Organisme : Horizon 2020 Framework Programme
ID : 739593
Organisme : GINOP
ID : 2.1-2016-0016
Organisme : GINOP
ID : 2.3.2-15-2016-00022
Organisme : Hungarian Scientific Research Fund
ID : 128322
Organisme : FEKUTSTRAT
ID : 20765-3/2018
Organisme : Ministry of Innovation and Technology
ID : TKP-BIOImaging
Références
Mol Imaging. 2013 Sep;12(6):376-87
pubmed: 23981783
PET Clin. 2019 Jul;14(3):317-329
pubmed: 31084772
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
J Nucl Med. 2012 Oct;53(10):1579-84
pubmed: 22904353
Nucl Med Commun. 1998 Feb;19(2):97-105
pubmed: 9548192
J Clin Oncol. 2014 Sep 20;32(27):3048-58
pubmed: 25113771
Cancer Treat Rev. 2016 Jul;48:42-9
pubmed: 27347669
Nucl Med Commun. 2016 Jul;37(7):689-98
pubmed: 27244584
J Nucl Med. 2011 May;52(5):800-7
pubmed: 21498533
J Nucl Med. 2015 Apr;56(4):538-44
pubmed: 25722446
World J Gastrointest Oncol. 2016 Jan 15;8(1):67-82
pubmed: 26798438
J Immunol. 2020 Jan 1;204(1):23-36
pubmed: 31767783
ISRN Radiol. 2013 Sep 02;2013:483069
pubmed: 24967280
Semin Nucl Med. 2018 Jan;48(1):76-81
pubmed: 29195620
Philos Trans A Math Phys Eng Sci. 2011 Nov 28;369(1955):4605-19
pubmed: 22006909
Clin Nucl Med. 2013 Aug;38(8):623-9
pubmed: 23797225
Int Immunol. 2009 Sep;21(9):1047-56
pubmed: 19625383
Int J Gynecol Cancer. 2011 Jan;21(1):22-7
pubmed: 21321526
Leuk Lymphoma. 2014 Mar;55(3):520-5
pubmed: 23701133
J Exp Med. 2019 Jan 7;216(1):176-194
pubmed: 30567719
Semin Nucl Med. 2018 Jul;48(4):359-366
pubmed: 29852945
ANZ J Surg. 2020 Sep;90(9):1592-1597
pubmed: 32129577
J Nucl Med. 2019 Oct;60(10):1437-1443
pubmed: 30850497
PLoS One. 2014 Jan 21;9(1):e86516
pubmed: 24466130
Mol Diagn Ther. 2014 Apr;18(2):153-73
pubmed: 24146172
Am J Pathol. 2006 Nov;169(5):1739-52
pubmed: 17071597
Radiographics. 2009 Mar-Apr;29(2):347-73
pubmed: 19325052
Pathol Oncol Res. 2016 Apr;22(2):421-30
pubmed: 26584567
Nucl Med Biol. 2005 Oct;32(7):719-25
pubmed: 16243647
Nucl Med Mol Imaging. 2011 Sep;45(3):169-76
pubmed: 24900000
Surgeon. 2020 Oct 3;:
pubmed: 33023847
Br J Radiol. 2018 Jan;91(1081):20170519
pubmed: 29099613
J Nucl Med. 2007 Feb;48(2):277-87
pubmed: 17268026
Semin Nucl Med. 2018 Jan;48(1):50-66
pubmed: 29195618
Cancer Treat Rep. 1978 Jan;62(1):1-11
pubmed: 626987
Blood. 2020 Apr 16;135(16):1396-1405
pubmed: 31978225
Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):181-200
pubmed: 19915839
PET Clin. 2016 Jan;11(1):57-64
pubmed: 26590444
J Nucl Med. 2011 Nov;52(11):1770-7
pubmed: 22045707
Sci Adv. 2016 May 27;2(5):e1600200
pubmed: 27386546
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219